{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:11:05Z","timestamp":1788480665665,"version":"build-2803163510"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":180,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008136","name":"Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008564","name":"Case Western Reserve University School of Medicine","doi-asserted-by":"publisher","award":["BFA2014-004"],"award-info":[{"award-number":["BFA2014-004"]}],"id":[{"id":"10.13039\/100008564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA43703"],"award-info":[{"award-number":["P30CA43703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA134878"],"award-info":[{"award-number":["R01CA134878"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Pharmacology and Drug Discovery"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.crphar.2022.100117","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T02:01:36Z","timestamp":1656900096000},"page":"100117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt\/ALK5\/Smad4-dependent mechanism"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-2630","authenticated-orcid":false,"given":"David","family":"Danielpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Corum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Bangalore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crphar.2022.100117_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.semcancer.2019.07.009","article-title":"PI3K\/Akt\/mTOR inhibitors in cancer: at the bench and bedside","volume":"59","author":"Alzahrani","year":"2019","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.crphar.2022.100117_bib2","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jcp.29975","article-title":"SPARC is a key mediator of TGF-beta-induced renal cancer metastasis","volume":"236","author":"Bao","year":"2021","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.crphar.2022.100117_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.08.046","article-title":"Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: a retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales)","volume":"158","author":"Cancel","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1634\/theoncologist.2016-0145","article-title":"A\u00a0phase ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma","volume":"21","author":"Carlo","year":"2016","journal-title":"Oncol."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.crphar.2022.100117_bib6","article-title":"Combination of mTOR and MAPK inhibitors-A potential way to treat renal cell carcinoma","volume":"4","author":"Chauhan","year":"2016","journal-title":"Med. Sci."},{"issue":"9","key":"10.1016\/j.crphar.2022.100117_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/1878-0261.12102","article-title":"MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701","volume":"11","author":"Chen","year":"2017","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.crphar.2022.100117_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ucl.2020.07.009","article-title":"Kidney cancer: an overview of current therapeutic approaches","volume":"47","author":"Chowdhury","year":"2020","journal-title":"Urol. Clin."},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1101\/gr.2334104","article-title":"Functional proteomics mapping of a human signaling pathway","volume":"14","author":"Colland","year":"2004","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib10","article-title":"Early cellular responses of prostate carcinoma cells to sepantronium bromide (YM155) involve suppression of mTORC1 by AMPK","volume":"9","author":"Danielpour","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crphar.2022.100117_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100076","article-title":"Hypoxia represses early responses of prostate and renal cancer cells to YM155 independent of HIF-1alpha and HIF-2alpha","volume":"3","author":"Danielpour","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0955-0674(98)80149-X","article-title":"Mechanisms and consequences of activation of protein kinase B\/Akt","volume":"10","author":"Downward","year":"1998","journal-title":"Curr. Opin. Cell Biol."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1074\/jbc.M305912200","article-title":"FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP\/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus","volume":"279","author":"Drenan","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.crphar.2022.100117_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2006.02.027","article-title":"IRS-1: auditing the effectiveness of mTOR inhibitors","volume":"9","author":"Easton","year":"2006","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.crphar.2022.100117_bib15","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2015.60.9727","volume":"33","author":"Flaherty","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"6","key":"10.1016\/j.crphar.2022.100117_bib16","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)","volume":"421","author":"Garcia-Martinez","year":"2009","journal-title":"Biochem. J."},{"issue":"18","key":"10.1016\/j.crphar.2022.100117_bib18","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1021\/jm0400247","article-title":"Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors","volume":"47","author":"Gellibert","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"issue":"11","key":"10.1016\/j.crphar.2022.100117_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081081","article-title":"Mammalian target of rapamycin complex 2 (mTORC2) is a critical determinant of bladder cancer invasion","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.crphar.2022.100117_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112767","article-title":"TGF-beta-Mediated epithelial-mesenchymal transition and cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"23","key":"10.1016\/j.crphar.2022.100117_bib21","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"6035","key":"10.1016\/j.crphar.2022.100117_bib22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.crphar.2022.100117_bib23","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.crphar.2022.100117_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14737140.2021.1868994","article-title":"The implementation of lenvatinib\/everolimus or lenvatinib\/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma","volume":"21","author":"Jacob","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib25","doi-asserted-by":"crossref","DOI":"10.1242\/dev.188490","article-title":"TGFbeta family signaling and development","volume":"148","author":"Jia","year":"2021","journal-title":"Development"},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bju.13185","article-title":"Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases","volume":"117","author":"Kalra","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.crphar.2022.100117_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10960","article-title":"Stability and function of adult vasculature is sustained by Akt\/Jagged1 signalling axis in endothelium","volume":"7","author":"Kerr","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat. Cell Biol."},{"issue":"18","key":"10.1016\/j.crphar.2022.100117_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189795","article-title":"Loss of Von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC)","volume":"22","author":"Kim","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","article-title":"Novel therapies emerging in oncology to target the TGF-beta pathway","volume":"14","author":"Kim","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"36","key":"10.1016\/j.crphar.2022.100117_bib32","doi-asserted-by":"crossref","first-page":"21920","DOI":"10.1074\/jbc.271.36.21920","article-title":"Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation","volume":"271","author":"Kohn","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1359\/jbmr.061005","article-title":"TGF-beta promotes the establishment of renal cell carcinoma bone metastasis","volume":"22","author":"Kominsky","year":"2007","journal-title":"J.\u00a0Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.crphar.2022.100117_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000449323","article-title":"Hypoxia-inducible factor-1alpha activates the transforming growth factor-beta\/SMAD3 pathway in kidney tubular epithelial cells","volume":"44","author":"Kushida","year":"2016","journal-title":"Am. J. Nephrol."},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib35","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"issue":"17","key":"10.1016\/j.crphar.2022.100117_bib36","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1080\/15384101.2019.1642069","article-title":"Interactions between TGF-beta type I receptor and hypoxia-inducible factor-alpha mediates a synergistic crosstalk leading to poor prognosis for patients with clear cell renal cell carcinoma","volume":"18","author":"Mallikarjuna","year":"2019","journal-title":"Cell Cycle"},{"issue":"536","key":"10.1016\/j.crphar.2022.100117_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib38","first-page":"1921","article-title":"Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2alpha expression in human renal cell carcinoma","volume":"189","author":"Maru","year":"2013","journal-title":"J.\u00a0Urol."},{"issue":"11","key":"10.1016\/j.crphar.2022.100117_bib39","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","article-title":"Development of therapeutic anti-JAGGED1 antibodies for cancer therapy","volume":"18","author":"Masiero","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.crphar.2022.100117_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-beta signal transduction","volume":"67","author":"Massague","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib41","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in cancer","volume":"134","author":"Massague","year":"2008","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.crphar.2022.100117_bib42","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/annonc\/mdy244","article-title":"First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer","volume":"29","author":"Massard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib43","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-Beta and the TGF-beta family: context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib44","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021865","article-title":"The discovery and early days of TGF-beta: a historical perspective","volume":"8","author":"Moses","year":"2016","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib45","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bbrc.2013.04.037","article-title":"Snail and Slug, key regulators of TGF-beta-induced EMT, are sufficient for the induction of single-cell invasion","volume":"435","author":"Naber","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib46","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1161\/01.RES.0000124300.76171.C9","article-title":"Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation","volume":"94","author":"Noseda","year":"2004","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.crphar.2022.100117_bib47","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbamcr.2010.09.001","article-title":"Jagged\/Notch signalling is required for a subset of TGFbeta1 responses in human kidney epithelial cells","volume":"1803","author":"Nyhan","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"25","key":"10.1016\/j.crphar.2022.100117_bib48","doi-asserted-by":"crossref","first-page":"40115","DOI":"10.18632\/oncotarget.16969","article-title":"Role of Delta-like 4 in Jagged1-induced tumour angiogenesis and tumour growth","volume":"8","author":"Oon","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.crphar.2022.100117_bib49","series-title":"StatPearls. Treasure Island (FL)","article-title":"Renal cancer","author":"Pandey","year":"2021"},{"key":"10.1016\/j.crphar.2022.100117_bib50","doi-asserted-by":"crossref","first-page":"7623","DOI":"10.2147\/CMAR.S267220","article-title":"Playing the devil's advocate: should we give a second chance to mTOR inhibition in renal clear cell carcinoma? - ie strategies to revert resistance to mTOR inhibitors","volume":"13","author":"Pezzicoli","year":"2021","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.crphar.2022.100117_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1083\/jcb.201108143","article-title":"Hic-5 promotes invadopodia formation and invasion during TGF-beta-induced epithelial-mesenchymal transition","volume":"197","author":"Pignatelli","year":"2012","journal-title":"J.\u00a0Cell Biol."},{"issue":"14","key":"10.1016\/j.crphar.2022.100117_bib52","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell."},{"issue":"6","key":"10.1016\/j.crphar.2022.100117_bib54","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.crphar.2022.100117_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.652273","article-title":"Biological significance of NOTCH signaling strength","volume":"9","author":"Shen","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.crphar.2022.100117_bib55","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol. Cancer Therapeut."},{"issue":"24","key":"10.1016\/j.crphar.2022.100117_bib56","doi-asserted-by":"crossref","first-page":"35917","DOI":"10.18632\/oncotarget.9177","article-title":"Transforming growth factor-beta promotes aggressiveness and invasion of clear cell renal cell carcinoma","volume":"7","author":"Sitaram","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1172\/JCI32086","article-title":"Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo","volume":"118","author":"Sjolund","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"issue":"8","key":"10.1016\/j.crphar.2022.100117_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023057","article-title":"The notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma","volume":"6","author":"Sjolund","year":"2011","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.crphar.2022.100117_bib59","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.234930","article-title":"Ras, PI3K and mTORC2 - three's a crowd?","volume":"133","author":"Smith","year":"2020","journal-title":"J.\u00a0Cell Sci."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/sj.emboj.7600917","article-title":"Novel roles of Akt and mTOR in suppressing TGF-beta\/ALK5-mediated Smad3 activation","volume":"25","author":"Song","year":"2006","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061896","article-title":"Critical role of a survivin\/TGF-beta\/mTORC1 axis in IGF-I-mediated growth of prostate epithelial cells","volume":"8","author":"Song","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.crphar.2022.100117_bib62","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/ijc.33349","article-title":"Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: final results of the MARC-2 trial","volume":"148","author":"Staehler","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11684-020-0812-7","article-title":"mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?","volume":"15","author":"Sun","year":"2021","journal-title":"Front. Med."},{"issue":"4","key":"10.1016\/j.crphar.2022.100117_bib64","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3892\/ijo.2012.1561","article-title":"Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma","volume":"41","author":"Taylor","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"24","key":"10.1016\/j.crphar.2022.100117_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246140","article-title":"Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes","volume":"20","author":"Tirpe","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"41","key":"10.1016\/j.crphar.2022.100117_bib66","doi-asserted-by":"crossref","first-page":"38052","DOI":"10.1074\/jbc.M106703200","article-title":"Amino acid and insulin signaling via the mTOR\/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells","volume":"276","author":"Tremblay","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"issue":"3","key":"10.1016\/j.crphar.2022.100117_bib67","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jcp.20991","article-title":"Hic-5 contributes to epithelial-mesenchymal transformation through a RhoA\/ROCK-dependent pathway","volume":"211","author":"Tumbarello","year":"2007","journal-title":"J.\u00a0Cell. Physiol."},{"issue":"6","key":"10.1016\/j.crphar.2022.100117_bib68","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/0008-5472.CAN-08-4312","article-title":"Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.crphar.2022.100117_bib69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40880-017-0203-x","article-title":"Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling","volume":"36","author":"Wang","year":"2017","journal-title":"Chin. J. Cancer"},{"issue":"6","key":"10.1016\/j.crphar.2022.100117_bib70","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/nan.12714","article-title":"TGF-beta activates pericytes via induction of the epithelial-to-mesenchymal transition protein SLUG in glioblastoma","volume":"47","author":"Wirsik","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"3","key":"10.1016\/j.crphar.2022.100117_bib71","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jjco\/hyq205","article-title":"High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma","volume":"41","author":"Wu","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib72","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3892\/or.2016.4687","article-title":"Selective suppression of Notch1 inhibits proliferation of renal cell carcinoma cells through JNK\/p38 pathway","volume":"35","author":"Wu","year":"2016","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.crphar.2022.100117_bib73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1066896909331993","article-title":"The expression and clinical significance of TGF-beta1 and MMP2 in human renal clear cell carcinoma","volume":"18","author":"Yang","year":"2010","journal-title":"Int. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib74","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.emboj.7600069","article-title":"Integration of TGF-beta\/Smad and Jagged1\/Notch signalling in epithelial-to-mesenchymal transition","volume":"23","author":"Zavadil","year":"2004","journal-title":"EMBO J."},{"issue":"51","key":"10.1016\/j.crphar.2022.100117_bib75","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1074\/jbc.M806480200","article-title":"S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2","volume":"283","author":"Zhang","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"issue":"5","key":"10.1016\/j.crphar.2022.100117_bib76","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1073\/pnas.95.5.2412","article-title":"Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells","volume":"95","author":"Zhou","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Current Research in Pharmacology and Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590257122000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:49:00Z","timestamp":1762922940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590257122000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":77,"alternative-id":["S2590257122000372"],"URL":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100117","relation":{},"ISSN":["2590-2571"],"issn-type":[{"value":"2590-2571","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt\/ALK5\/Smad4-dependent mechanism","name":"articletitle","label":"Article Title"},{"value":"Current Research in Pharmacology and Drug Discovery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crphar.2022.100117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100117"}}